Arcutis Biotherapeutics (ARQT) News Today

Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) shares are being supported by continued optimism around the company’s commercial growth and analyst backing, even as recent earnings results and insider sales create some near-term caution.

• Positive Sentiment: HC Wainwright maintained a Buy rating and $34 price target on Arcutis Biotherapeutics while raising near-term EPS estimates for 2026 quarters, reinforcing the view that earnings could improve as ZORYVE sales scale. Article Title
• Positive Sentiment: Needham also reiterated its Buy rating with a $36 target, helping sentiment by signaling that analysts still see meaningful upside from current levels. Article Title
• Positive Sentiment: The company reported a $105.4 million quarterly revenue beat and highlighted strong ZORYVE momentum, including commercial growth and pipeline progress, which remains a key driver for investor enthusiasm. Article Title
• Neutral Sentiment: Arcutis announced inducement grants to 40 new hires, a routine equity compensation move that signals continued hiring but is not likely to materially change the stock’s near-term outlook. Article Title
• Neutral Sentiment: HC Wainwright’s mix of higher and lower out-year estimates suggests analysts remain constructive overall, but are still fine-tuning the longer-term earnings model. Article Title
• Negative Sentiment: Q1 EPS missed expectations, showing Arcutis is still spending heavily as it grows; that profitability gap could limit upside if investors focus on margins rather than sales growth. Article Title
• Negative Sentiment: Several insiders sold shares under pre-arranged 10b5-1 plans, which is routine, but clustered selling can still weigh on sentiment in the short term. Article Title

Overall, ARQT appears to be rising more on continued revenue momentum and analyst support than on any single new catalyst, while earnings misses and insider selling remain the main reasons investors may be cautious.